|
|
|
| Relationship between the Phosphatidylinositol-3 Kinase p110 Catalytic Subunit Gene Mutation of Circulating Tumor Cells and Clinicopathological Characteristics in Breast Cancer Patients |
| WANG Qiao-ge, YAN Feng-na |
| Department of Pathology,Northwest Women and Children's Hospital,Xi'an 710061 |
|
|
|
|
Abstract 【Objective】To explore the relationship of phosphatidylinositol-3 kinase p110 catalytic subunit (PIK3CA) gene mutations in circulating tumor cells with clinicopathological characteristics in breast cancer patients.【Methods】Seventy-eight breast cancer patients admitted to the hospital were selected as the observation group, and 72 healthy women who came to the hospital for physical examination during the same period were selected as the control group. The microdrop digital technology was used to examine the PIK3CA mutations in the peripheral blood circulating tumor cells in the two groups, and the clinical characteristics of breast cancer patients were counted. Kaplan-Meier was used for survival analysis.【Results】The positive expression rate of peripheral blood PIK3CA in peripheral blood circulating tumor cells of breast cancer patients were higher than that in the control group (P<0.05). The PIK3CA gene mutation rate of circulating tumor cells in the peripheral blood of 78 breast cancer patients was 29.49% (23/78). The clinical stage, degree of differentiation, and Ki-67 index composition of patients with PIK3CA gene mutations in peripheral blood circulating tumor cells of breast cancer were significantly different from those withou tmutation patients, the difference was statistically significant (P<0.05). The 3-year survival of breast cancer patients showed that the survival rate of patients with PIK3CA gene mutations in peripheral blood circulating tumor cells was 43.48% (13/23), which was lower than that of non-mutated patients 83.02% (44/53).The difference between the two were statistically significant (P<0.05).【Conclusion】The clinical stages Ⅲ-Ⅳ, poor differentiation, and Ki-67 index ≥20% are all related to the PIK3CA gene mutation in circulating tumor cells of breast cancer patients.It suggests that PIK3CA gene mutation has important value in the prognosis of breast cancer.
|
|
Received: 19 October 2021
|
|
|
|
|
|
[1] QASEEM A,LIN J S,MUSTAFA R A,et al. Screening for breast cancer in average-risk women:a guidance statement from the american college of physicians[J].Ann Intern Med,2019,170(8):547-560.
[2] ARKADIUS P,VOLKMAR M,JENS H,et al. Circulating tumor cells in metastatic breast cancer:clinical relevance and biological potential[J].Curr Opin Obstet Gynecol,2019,31(1):76-81.
[3] ANDRÉ F,CIIRUELOS E,RUBOVSZKY G,et al. Alpelisib for PIK3CA-Mutated,hormone receptor-positive advanced breast cancer[J].N Engl J Med,2019,380(20):1929-1940.
[4] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):692-754.
[5] COUGHLIN S S. Social determinants of breast cancer risk,stage,and survival[J].Breast Cancer Res Treat,2019,177(3):537-548.
[6] SLEPICKA P F,CYRILL S L,DOS SANTOS C O. Pregnancy and breast cancer:pathways to understand risk and prevention[J].Trends Mol Med,2019,25(10):866-881.
[7] ALOWIRI N H,HANAFY S M,HALEEM R A,et al. PIK3CA and PTEN genes expressions in breast cancer[J]. Asian Pac J Cancer Prev,2019,20(9):2841-2846.
[8] RADOVICH M,JIANG G,HANCOCK B A,et al. Association of circulating tumor dna and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer:preplanned secondary analysis of the BRE12-158 randomized clinical trial[J].JAMA Oncol,2020,6(9):1410-1415.
[9] SCHOCHTER F,FRIEDL T W P,deGREGORIO A,et al. Are circulating tumor cells (CTCs) ready for clinical use in breast cancer:an overview of completed and ongoing trials using ctcs for clinical treatment decisions[J].Cells,2019,8(11):1412-1420.
[10] HASHMI A A,HASHMI K A,IRFAN M,et al. Ki-67 index in intrinsic breast cancer subtypes and its association with prognostic parameters[J].BMC Res Notes,2019,12(1):605-612.
[11] XING Y,LIN N U,MAURER M A,et al. Phase Ⅱ trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations,and/or PTEN loss/PTEN mutation[J].Breast Cancer Res,2019,21(1):78-85.
[12] 杨波,张晓燕,曾鸿,等. PIK3CA和TP53基因突变与乳腺癌分子分型及组织学分级相关性的研究[J].中国普外基础与临床杂志,2019,26(5):573-578. |
|
|
|
2022, Vol. 39 
